Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options

Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy...

Descripción completa

Detalles Bibliográficos
Autores principales: Isidro, Maria Luisa, Cordido, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991023/
https://www.ncbi.nlm.nih.gov/pubmed/27713245
http://dx.doi.org/10.3390/ph3010125
_version_ 1782312365825458176
author Isidro, Maria Luisa
Cordido, Fernando
author_facet Isidro, Maria Luisa
Cordido, Fernando
author_sort Isidro, Maria Luisa
collection PubMed
description Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options.
format Online
Article
Text
id pubmed-3991023
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Molecular Diversity Preservation International
record_format MEDLINE/PubMed
spelling pubmed-39910232014-04-18 Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options Isidro, Maria Luisa Cordido, Fernando Pharmaceuticals (Basel) Review Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options. Molecular Diversity Preservation International 2010-01-12 /pmc/articles/PMC3991023/ /pubmed/27713245 http://dx.doi.org/10.3390/ph3010125 Text en © 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Isidro, Maria Luisa
Cordido, Fernando
Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
title Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
title_full Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
title_fullStr Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
title_full_unstemmed Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
title_short Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
title_sort approved and off-label uses of obesity medications, and potential new pharmacologic treatment options
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991023/
https://www.ncbi.nlm.nih.gov/pubmed/27713245
http://dx.doi.org/10.3390/ph3010125
work_keys_str_mv AT isidromarialuisa approvedandofflabelusesofobesitymedicationsandpotentialnewpharmacologictreatmentoptions
AT cordidofernando approvedandofflabelusesofobesitymedicationsandpotentialnewpharmacologictreatmentoptions

Ejemplares similares